Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 6857625, 6 pages
http://dx.doi.org/10.1155/2016/6857625
Research Article

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

1Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea
2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
3Department of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea
4Department of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea

Received 9 September 2015; Revised 30 October 2015; Accepted 1 November 2015

Academic Editor: Haruhiko Sugimura

Copyright © 2016 Joo Young Jung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Serjomataram, M. Ervik et al., LOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Lyon, France, International Agency for Research on Cancer, 2013, http://globocan.iarc.fr.
  2. A. Cuschieri, S. Weeden, J. Fielding et al., “Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial,” British Journal of Cancer, vol. 79, no. 9-10, pp. 1522–1530, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig, “Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2903–2909, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Webb, D. Cunningham, J. H. Scarffe et al., “Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 261–267, 1997. View at Google Scholar · View at Scopus
  5. T. Waddell, I. Chau, D. Cunningham et al., “Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 481–489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin et al., “Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4991–4997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Koizumi, H. Narahara, T. Hara et al., “S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial,” The Lancet Oncology, vol. 9, no. 3, pp. 215–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Y.-K. Kang, W.-K. Kang, D.-B. Shin et al., “Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial,” Annals of Oncology, vol. 20, no. 4, pp. 666–673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Louvet, T. André, J. M. Tigaud et al., “Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients,” Journal of Clinical Oncology, vol. 20, no. 23, pp. 4543–4548, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” The New England Journal of Medicine, vol. 358, no. 1, pp. 36–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. C. Thuss-Patience, A. Kretzschmar, Y. Dogan et al., “Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts,” British Journal of Cancer, vol. 105, no. 4, pp. 505–512, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Yamaguchi, T. Shimamura, I. Hyodo et al., “Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer,” British Journal of Cancer, vol. 94, no. 12, pp. 1803–1808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Y. Zang, D. H. Yang, H. W. Lee et al., “Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 3, pp. 509–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Y. Zang, D. H. Yang, M.-J. Kim et al., “Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 5, pp. 877–883, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. H. S. Kim, M. H. Ryu, D. Y. Zang et al., “Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer,” Gastric Cancer, 2015. View at Publisher · View at Google Scholar
  16. P. C. Thuss-Patience, A. Kretzschmar, D. Bichev et al., “Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO),” European Journal of Cancer, vol. 47, no. 15, pp. 2306–2314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. Kang, S. I. Lee, H. Lim do et al., “Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1513–1518, 2012. View at Publisher · View at Google Scholar
  18. H. E. R. Ford, A. Marshall, J. A. Bridgewater et al., “Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial,” The Lancet Oncology, vol. 15, no. 1, pp. 78–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Sym, M.-H. Ryu, J.-L. Lee et al., “Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane,” American Journal of Clinical Oncology, vol. 31, no. 2, pp. 151–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. H. Kim, G.-W. Lee, S. I. Go et al., “A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen,” American Journal of Clinical Oncology, vol. 33, no. 6, pp. 572–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. J. Sym, J. Hong, J. Park et al., “A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 2, pp. 481–488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. S. Fuchs, J. Marshall, E. Mitchell et al., “Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4779–4786, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. S. Kim, H. J. Kim, S. Y. Kim et al., “Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: a meta-analysis,” Annals of Oncology, vol. 24, no. 11, Article ID mdt351, pp. 2850–2854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Maugeri-Saccà, L. Pizzuti, D. Sergi et al., “FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort,” Journal of Experimental & Clinical Cancer Research, vol. 32, article 67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Mochizuki, N. Ohashi, H. Kojima et al., “CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702),” Cancer Chemotherapy and Pharmacology, vol. 72, no. 3, pp. 629–635, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. N. Sendur, N. Ozdemir, T. Özatli et al., “Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen,” Medical Oncology, vol. 31, article 153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Higuchi, S. Tanabe, K. Shimada et al., “Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial),” European Journal of Cancer, vol. 50, no. 8, pp. 1437–1445, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. F.-H. Han, H.-M. Li, D.-H. Zheng, Y.-L. He, and W.-H. Zhan, “The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma,” European Journal of Surgical Oncology, vol. 36, no. 12, pp. 1172–1179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Wilke, K. Muro, E. Van Cutsem et al., “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial,” The Lancet Oncology, vol. 15, no. 11, pp. 1224–1235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Tabernero, T. Yoshino, A. L. Cohn et al., “Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study,” The Lancet Oncology, vol. 16, no. 5, pp. 499–508, 2015. View at Publisher · View at Google Scholar
  32. V. Catalano, F. Graziano, D. Santini et al., “Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?” British Journal of Cancer, vol. 99, no. 9, pp. 1402–1407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, J. Oates, and P. J. Ross, “Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2395–2403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Lee, T. Lim, J. E. Uhm et al., “Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma,” Annals of Oncology, vol. 18, no. 5, pp. 886–891, 2007. View at Publisher · View at Google Scholar · View at Scopus